RegulatoryOfficial

Commission authorises ADCOMFO (omalizumab) for Advanz Pharma under Decision (2026) 8241

🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026

The European Commission has granted a new marketing authorisation for omalizumab product ADCOMFO, held by Advanz Pharma Limited, adding another omalizumab option to the EU market.

The European Commission has granted a marketing authorisation for ADCOMFO (omalizumab), with Advanz Pharma Limited as marketing authorisation holder. The authorisation was issued under Commission Decision (2026) 8241 of 12 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.

More Regulatory All →